KRAS(G12D) Drives Lepidic Adenocarcinoma Through Stem-Cell Reprogramming

Scientists demonstrated a different scenario: expression of KRAS(G12D) in differentiated AT1 cells reprograms them slowly and asynchronously back into AT2 stem cells that go on to generate indolent tumors.